UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 08, 2022, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and six-months ended June 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is furnished as part of this report:
Exhibit number |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
RxSight, Inc. |
|
|
|
|
Date: |
August 08, 2022 |
By: |
/s/ Shelley Thunen |
|
|
|
Name: Shelley Thunen |
Exhibit 99.1
RxSight, Inc. Reports Second Quarter 2022 Financial Results
Aliso Viejo, Calif. (NASDAQ: RXST) – August 8, 2022 – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2022.
Key Quarterly Highlights:
“In the second quarter of 2022, RxSight continued to establish a track record of strong year-over-year and sequential growth, driven by vigorous demand for our LDD and accelerating utilization of our LAL,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “Our progress thus far reflects the powerful benefits doctors and patients derive when they choose our unique LAL system, enabling them to achieve excellent vision without glasses or compromises.”
Second Quarter Financial Results
In the second quarter of 2022, total revenue was $11.4 million, an increase of 132% compared to the second quarter of 2021. Revenue growth was driven by a 92% increase in LDD revenue and a 199% increase in LAL revenue, as compared to the second quarter of 2021.
Gross profit for the second quarter of 2022 was $4.8 million (42% of revenue), an increase of $5.6 million or 690% compared to the gross (loss) of $(0.8) million ((17)% of revenue) for the second quarter of 2021.
Total operating expenses for the second quarter of 2022 were $20.6 million, a 57.5% increase from $13.1 million in the second quarter of 2021. The rise in operating expenses was primarily due to higher sales and marketing headcount to support the company’s growth plans, the cost associated with operating as a public company, and an increase of $1.4 million in stock-based compensation expense.
In the second quarter of 2022, the company reported a net loss of $(16.7) million, or $(0.61) per basic and diluted share, compared to net loss of $(13.5) million, or $(3.28) and $(3.53) per share on a basic and diluted basis, respectively, in the second quarter of 2021.
The adjusted net loss in the second quarter of 2022 was $(13.8) million, or $(0.50) per basic and diluted share, compared to an adjusted net loss of $(13.3) million, or $(3.24) per basic and diluted share in the second quarter of 2021.
Cash, cash equivalents and short-term investments as of June 30, 2022, were $128.6 million and long-term debt was $39.9 million.
Financial Outlook
Based on its second quarter 2022 performance, RxSight has revised its 2022 full year revenue guidance to a range of $44.0 million to $46.0 million, compared to prior guidance of $41.5 million to $45.5 million. The revised guidance range implies an annual growth rate versus 2021 of 95% to 104%. The company has increased its 2022 gross margin guidance range to 37% to 38% of revenue, up from the previous range of 35% to 36% of revenue. The Company also narrowed its operating expense guidance to a range of $88.0 million to $90.0 million compared to prior guidance of $86.0 million to $90.0 million.
Conference Call
On Monday, August 8, 2022, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2022 financial results. Participants may register for the call here or through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended participants join 10 minutes prior to the event start time.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including the Company establishing a track record of strong year-over-year and sequential growth driven by the vigorous demand for the Company’s LDD and accelerating utilization of its LAL and the powerful benefits doctors and patients derive when they choose the LAL system enabling them to achieve excellent vision without glasses or compromises. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
IR@rxsight.com
RxSIGHT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(In thousands, except share and per share amounts)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Sales |
|
$ |
11,360 |
|
|
$ |
4,897 |
|
|
$ |
20,301 |
|
|
$ |
8,381 |
|
Cost of sales |
|
|
6,572 |
|
|
|
5,709 |
|
|
|
11,752 |
|
|
|
8,074 |
|
Gross profit (loss) |
|
|
4,788 |
|
|
|
(812 |
) |
|
|
8,549 |
|
|
|
307 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
14,388 |
|
|
|
6,502 |
|
|
|
28,008 |
|
|
|
12,113 |
|
Research and development |
|
|
6,192 |
|
|
|
6,563 |
|
|
|
12,911 |
|
|
|
13,206 |
|
Total operating expenses |
|
|
20,580 |
|
|
|
13,065 |
|
|
|
40,919 |
|
|
|
25,319 |
|
Loss from operations |
|
|
(15,792 |
) |
|
|
(13,877 |
) |
|
|
(32,370 |
) |
|
|
(25,012 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Change in fair value of warrants |
|
|
— |
|
|
|
1,214 |
|
|
|
— |
|
|
|
1,214 |
|
Expiration of warrant |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5,018 |
|
Interest expense |
|
|
(1,136 |
) |
|
|
(826 |
) |
|
|
(2,196 |
) |
|
|
(1,524 |
) |
Interest and other income |
|
|
196 |
|
|
|
15 |
|
|
|
242 |
|
|
|
32 |
|
Loss before income taxes |
|
|
(16,732 |
) |
|
|
(13,474 |
) |
|
|
(34,324 |
) |
|
|
(20,272 |
) |
Income tax expense |
|
|
0 |
|
|
|
3 |
|
|
|
4 |
|
|
|
10 |
|
Net loss |
|
$ |
(16,732 |
) |
|
$ |
(13,477 |
) |
|
$ |
(34,328 |
) |
|
$ |
(20,282 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized (loss) gain on short-term investments |
|
|
(76 |
) |
|
|
(4 |
) |
|
|
(150 |
) |
|
|
3 |
|
Foreign currency translation (loss) gain |
|
|
(9 |
) |
|
|
1 |
|
|
|
(13 |
) |
|
|
(3 |
) |
Total other comprehensive loss |
|
|
(85 |
) |
|
|
(3 |
) |
|
|
(163 |
) |
|
|
— |
|
Comprehensive loss |
|
$ |
(16,817 |
) |
|
$ |
(13,480 |
) |
|
$ |
(34,491 |
) |
|
$ |
(20,282 |
) |
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Attributable to Series G common stock, basic and diluted |
|
$ |
— |
|
|
$ |
(0.32 |
) |
|
$ |
— |
|
|
$ |
(0.48 |
) |
Attributable to common stock, basic |
|
$ |
(0.61 |
) |
|
$ |
(3.28 |
) |
|
$ |
(1.25 |
) |
|
$ |
(5.00 |
) |
Attributable to common stock, diluted |
|
$ |
(0.61 |
) |
|
$ |
(3.53 |
) |
|
$ |
(1.25 |
) |
|
$ |
(5.23 |
) |
Weighted-average shares used in computing net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Attributable to Series G common stock, basic and diluted |
|
|
— |
|
|
|
1 |
|
|
|
— |
|
|
|
1 |
|
Attributable to common stock, basic |
|
|
27,559,908 |
|
|
|
4,106,403 |
|
|
|
27,493,130 |
|
|
|
4,052,920 |
|
Attributable to common stock, diluted |
|
|
27,559,908 |
|
|
|
4,166,439 |
|
|
|
27,493,130 |
|
|
|
4,113,249 |
|
RxSIGHT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share amounts)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2022 |
|
|
2021 |
|
||
|
|
(Unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
24,004 |
|
|
$ |
24,361 |
|
Short-term investments |
|
|
104,616 |
|
|
|
134,971 |
|
Accounts receivable |
|
|
6,884 |
|
|
|
4,862 |
|
Inventories |
|
|
11,622 |
|
|
|
8,032 |
|
Prepaid and other current assets |
|
|
2,802 |
|
|
|
4,069 |
|
Total current assets |
|
|
149,928 |
|
|
|
176,295 |
|
Property and equipment, net |
|
|
11,083 |
|
|
|
11,217 |
|
Operating leases right-of-use assets |
|
|
4,704 |
|
|
|
4,284 |
|
Restricted cash |
|
|
811 |
|
|
|
811 |
|
Other assets |
|
|
188 |
|
|
|
114 |
|
Total assets |
|
$ |
166,714 |
|
|
$ |
192,721 |
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
3,277 |
|
|
$ |
1,689 |
|
Accrued expenses and other current liabilities |
|
|
7,877 |
|
|
|
7,859 |
|
Lease liabilities |
|
|
1,842 |
|
|
|
1,529 |
|
Total current liabilities |
|
|
12,996 |
|
|
|
11,077 |
|
Long-term lease liabilities |
|
|
3,851 |
|
|
|
3,642 |
|
Term loan, net |
|
|
39,881 |
|
|
|
39,760 |
|
Total liabilities |
|
|
56,728 |
|
|
|
54,479 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
|
|
||
Common stock, $0.001 par value, 900,000,000 shares authorized, 27,631,479 shares issued and |
|
|
27 |
|
|
|
27 |
|
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
623,746 |
|
|
|
617,511 |
|
Accumulated other comprehensive loss |
|
|
(183 |
) |
|
|
(20 |
) |
Accumulated deficit |
|
|
(513,604 |
) |
|
|
(479,276 |
) |
Total stockholders' equity |
|
|
109,986 |
|
|
|
138,242 |
|
Total liabilities and stockholders' equity |
|
$ |
166,714 |
|
|
$ |
192,721 |
|
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including Adjusted net loss, and Adjusted net loss per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense and change in fair value of warrants because these are non-cash in nature and excluding these items provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Loss and Adjusted Net Loss Per Share
Adjusted net loss is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation and (ii) change in fair value of warrants. We believe Adjusted net loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. Adjusted net loss for Series G Common Stock is not impacted by the adjustments.
Reconciliations of Net loss to Adjusted net loss and the presentation of Adjusted net loss per share, basic and diluted, are as follows:
RxSIGHT, INC.
GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED)
(In thousands, except share and per share amounts)
|
|
Three months ended June 30, |
|
|
Six months ended June 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss available to stockholders, basic |
|
$ |
(16,732 |
) |
|
$ |
(13,477 |
) |
|
$ |
(34,328 |
) |
|
$ |
(20,282 |
) |
Net loss available to stockholders, diluted |
|
|
(16,732 |
) |
|
|
(14,691 |
) |
|
|
(34,328 |
) |
|
|
(21,496 |
) |
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Stock-based compensation |
|
|
2,904 |
|
|
|
1,406 |
|
|
|
5,553 |
|
|
|
2,645 |
|
Change in fair value of warrants |
|
|
— |
|
|
|
(1,214 |
) |
|
|
— |
|
|
|
(1,214 |
) |
Adjusted net loss available to common stockholders, basic: |
|
$ |
(13,828 |
) |
|
$ |
(13,285 |
) |
|
$ |
(28,775 |
) |
|
$ |
(18,851 |
) |
Adjusted net loss available to common stockholders, diluted: |
|
$ |
(13,828 |
) |
|
$ |
(13,285 |
) |
|
$ |
(28,775 |
) |
|
$ |
(18,851 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average shares outstanding, basic |
|
|
27,559,908 |
|
|
|
4,106,403 |
|
|
|
27,493,130 |
|
|
|
4,052,920 |
|
Weighted-average shares outstanding, diluted |
|
|
27,559,908 |
|
|
|
4,166,439 |
|
|
|
27,493,130 |
|
|
|
4,113,249 |
|
Adjusted net loss per share, basic |
|
$ |
(0.50 |
) |
|
$ |
(3.24 |
) |
|
$ |
(1.05 |
) |
|
$ |
(4.65 |
) |
Adjusted net loss per share, diluted |
|
$ |
(0.50 |
) |
|
$ |
(3.24 |
) |
|
$ |
(1.05 |
) |
|
$ |
(4.65 |
) |